middle.news
How Immutep’s LAG-3 Trials Are Reshaping Lung and Head & Neck Cancer Treatment
8:39am on Wednesday 30th of July, 2025 AEST
•
Biotechnology
Read Story
How Immutep’s LAG-3 Trials Are Reshaping Lung and Head & Neck Cancer Treatment
8:39am on Wednesday 30th of July, 2025 AEST
Key Points
TACTI-004 Phase III trial in first-line non-small cell lung cancer expanding globally
INSIGHT-003 trial shows 60.8% response rate and 90.2% disease control in NSCLC
TACTI-003 Phase IIb trial reports 17.6-month median overall survival in head and neck cancer
EFTISARC-NEO Phase II trial meets primary endpoint in soft tissue sarcoma
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
IMM
OPEN ARTICLE